Treatment of non-small-cell lung cancer with erlotinib or gefitinib

Vince D. Cataldo, Don L. Gibbons, Roman Perez-Soler, Alfonso Quintás-Cardama

Research output: Contribution to journalArticle

278 Citations (Scopus)

Abstract

A 64-year-old woman who has never smoked receives the diagnosis of stage I adenocarcinoma of the lung and undergoes right upper lobectomy. One year later, bone and liver metastases develop. She is treated with carboplatin, paclitaxel, and bevacizumab, but progressive bone metastases are noted after 6 weeks of therapy. An oncologist recommends the initiation of erlotinib therapy.

Original languageEnglish (US)
Pages (from-to)947-955
Number of pages9
JournalNew England Journal of Medicine
Volume364
Issue number10
DOIs
StatePublished - Mar 10 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Bone and Bones
Carboplatin
Paclitaxel
Liver
Therapeutics
gefitinib
Erlotinib Hydrochloride
Bevacizumab
Oncologists
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of non-small-cell lung cancer with erlotinib or gefitinib. / Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintás-Cardama, Alfonso.

In: New England Journal of Medicine, Vol. 364, No. 10, 10.03.2011, p. 947-955.

Research output: Contribution to journalArticle

Cataldo, Vince D. ; Gibbons, Don L. ; Perez-Soler, Roman ; Quintás-Cardama, Alfonso. / Treatment of non-small-cell lung cancer with erlotinib or gefitinib. In: New England Journal of Medicine. 2011 ; Vol. 364, No. 10. pp. 947-955.
@article{278a8e54e83e4f6f84c7bdc72ed50bcb,
title = "Treatment of non-small-cell lung cancer with erlotinib or gefitinib",
abstract = "A 64-year-old woman who has never smoked receives the diagnosis of stage I adenocarcinoma of the lung and undergoes right upper lobectomy. One year later, bone and liver metastases develop. She is treated with carboplatin, paclitaxel, and bevacizumab, but progressive bone metastases are noted after 6 weeks of therapy. An oncologist recommends the initiation of erlotinib therapy.",
author = "Cataldo, {Vince D.} and Gibbons, {Don L.} and Roman Perez-Soler and Alfonso Quint{\'a}s-Cardama",
year = "2011",
month = "3",
day = "10",
doi = "10.1056/NEJMct0807960",
language = "English (US)",
volume = "364",
pages = "947--955",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Treatment of non-small-cell lung cancer with erlotinib or gefitinib

AU - Cataldo, Vince D.

AU - Gibbons, Don L.

AU - Perez-Soler, Roman

AU - Quintás-Cardama, Alfonso

PY - 2011/3/10

Y1 - 2011/3/10

N2 - A 64-year-old woman who has never smoked receives the diagnosis of stage I adenocarcinoma of the lung and undergoes right upper lobectomy. One year later, bone and liver metastases develop. She is treated with carboplatin, paclitaxel, and bevacizumab, but progressive bone metastases are noted after 6 weeks of therapy. An oncologist recommends the initiation of erlotinib therapy.

AB - A 64-year-old woman who has never smoked receives the diagnosis of stage I adenocarcinoma of the lung and undergoes right upper lobectomy. One year later, bone and liver metastases develop. She is treated with carboplatin, paclitaxel, and bevacizumab, but progressive bone metastases are noted after 6 weeks of therapy. An oncologist recommends the initiation of erlotinib therapy.

UR - http://www.scopus.com/inward/record.url?scp=79952376771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952376771&partnerID=8YFLogxK

U2 - 10.1056/NEJMct0807960

DO - 10.1056/NEJMct0807960

M3 - Article

C2 - 21388312

AN - SCOPUS:79952376771

VL - 364

SP - 947

EP - 955

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -